BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9103402)

  • 1. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
    Codegoni AM; Broggini M; Pitelli MR; Pantarotto M; Torri V; Mangioni C; D'Incalci M
    Gynecol Oncol; 1997 Apr; 65(1):130-7. PubMed ID: 9103402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM; Tian C; Reed E
    Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple drug resistance parameter expression in ovarian cancer.
    Joncourt F; Buser K; Altermatt H; Bacchi M; Oberli A; Cerny T
    Gynecol Oncol; 1998 Aug; 70(2):176-82. PubMed ID: 9740686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
    Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y
    Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
    J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
    Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
    Dabholkar M; Vionnet J; Bostick-Bruton F; Yu JJ; Reed E
    J Clin Invest; 1994 Aug; 94(2):703-8. PubMed ID: 8040325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin.
    Kim R; Hirabayashi N; Nishiyama M; Saeki S; Toge T; Okada K
    Anticancer Res; 1991; 11(1):429-31. PubMed ID: 1850221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance mechanisms in chronic lymphocytic leukemia.
    Ribrag V; Massade L; Faussat AM; Dreyfus F; Bayle C; Gouyette A; Marie JP
    Leukemia; 1996 Dec; 10(12):1944-9. PubMed ID: 8946935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
    Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
    Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes].
    Luan YZ; Li L; Li DR; Zhang W; Tang BJ
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):403-7. PubMed ID: 15312326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
    Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
    van der Zee AG; Hollema H; de Jong S; Boonstra H; Gouw A; Willemse PH; Zijlstra JG; de Vries EG
    Cancer Res; 1991 Nov; 51(21):5915-20. PubMed ID: 1682037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.